This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

CLAAD Warns Of Increase In Prescription Drug Overdoses

Opioid Pain Relievers without Safety Features Could Return to the Market in January

WASHINGTON, Nov. 12, 2012 /PRNewswire-USNewswire/ -- Today, a national organization dedicated to reducing prescription drug abuse urged communities to take extra precautions to prevent medication overdoses.  The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) warned that pain pills without added safety features are expected to flood back into communities in the coming weeks unless the Food and Drug Administration (FDA) takes preventive action. 

In recent years, the makers of the powerful opioid pain relievers OxyContin and Opana removed their traditional products from the market in favor of new versions designed to impede certain forms of intentional abuse.  Preliminary, peer-reviewed evidence indicates that dealers and abusers have less interest in the new drugs with abuse-deterrent features.[1]  The new medications cost no more to consumers than their prior formulations. 

"Pharmaceutical companies have an obligation to make their products safer," said Michael Barnes, spokesman for CLAAD. 

Several drug companies have asked the FDA to approve generic versions of these medications that do not have abuse-deterrent properties.  The FDA could allow the old formulations of the drugs to return to market as early as January 2013. 

"Parents, health care providers, and law enforcement must be prepared to confront the resurgence of more readily abused pain medications, and the overdoses that could follow," Barnes said. 

Earlier this month, CLAAD and nine other public health and safety organizations sent a letter to the FDA urging it to take swift action to foster the widespread adoption of abuse-deterrent medications and to prevent the marketing of generic versions of the drugs that do not have similar safety features. 

A bill before the U.S. House of Representatives, H.R. 6160, would require all manufacturers of opioid pain relievers to utilize abuse-deterrent technologies.  However, the measure is not likely to pass before January.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs